Macy’s (NYSE:M) lost about 20% of its value over the past three months amid concerns about its slowing growth and lackluster turnaround efforts. A big guidance cut in January, which was attributed to soft holiday sales, seemingly confirmed those fears.
Despite those challenges, Macy’s fourth quarter numbers still beat analysts’ expectations. Its revenue fell 2.5% annually to $8.46 billion, but beat estimates by $20 million. However, Macy’s fourth quarter included one less week than the prior year quarter. Its comparable store sales, which excludes that impact, rose 0.4% on an owned basis and 0.7% on an owned plus licensed basis. On a “shifted” basis, which aligns with the calendar years more closely, its owned plus licensed comps rose 2%.
Image source: Macy’s.
Macy’s adjusted net income fell 3% to $850 million. Its adjusted earnings declined 4% to $2.73 per share, but still beat expectations by $0.20. On a GAAP basis, which includes certain one-time benefits and charges, its EPS declined 46% to $2.37.
Hot Oil Stocks To Buy For 2021: BioPharmX Corporation(BPMX)
BioPharmX Corporation, a specialty pharmaceutical company, focuses on the development of novel drug delivery products for women’s health, dermatology, and otolaryngology markets. The company offers prescription, over-the-counter (OTC), and supplement products in oral, topical, inhalant, and/or injectable forms. It provides VI2OLET iodine, an OTC dietary supplement molecular iodine tablet that promotes overall breast health and for the alleviation of benign breast pain associated with fibrocystic breast condition. The companys clinical-stage product candidates include BPX03, a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia; and BPX01, a non-lipophilic topical antibiotic for the treatment of acne. It serves pharmaceutical companies; physician’s practices, including OB-Gyn’s, dermatologists, and general practioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC for the development of molecular iodine products; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.
- [By Stephan Byrd]
Shares of Biopharmx Corp (NYSEAMERICAN:BPMX) were up 4.8% during mid-day trading on Tuesday . The stock traded as high as $0.22 and last traded at $0.20. Approximately 32,497 shares were traded during trading, a decline of 100% from the average daily volume of 8,266,355 shares. The stock had previously closed at $0.21.
Hot Oil Stocks To Buy For 2021: Tiptree Financial Inc.(TIPT)
Tiptree Financial is a diversified holding company that primarily acquires and manages controlling interests of operating businesses. The Company, whose operations date back to 2007, currently has subsidiaries that operate in the following four segments: insurance and insurance services, specialty finance, asset management and real estate. The Company’s principal investments are included in a corporate and other segment. Tiptree Financial’s Class A common stock trades on the NASDAQ Capital Market. All of Tiptree Financial’s Class B common stock is owned by TFP. Tiptree Financial’s Class B common stock has voting but no economic rights.
From July 1, 2014, the limited partners of TFP (other than Tiptree Financial itself) have been provided with the opportunity to exchange TFP partnership units for Tiptree Financial Class A common stock at a rate of 2.798 shares of Class A common stock per partnership unit. Advisors’ Opinion:
- [By Stephan Byrd]
Tiptree Inc (NASDAQ:TIPT) CFO Sandra Bell sold 8,682 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $6.55, for a total transaction of $56,867.10. Following the completion of the sale, the chief financial officer now directly owns 41,881 shares of the company’s stock, valued at $274,320.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
- [By Tim Melvin]
This week, I ran across Tiptree Inc. (Nasdaq: TIPT) on the list of stocks with the highest VQScores. Tiptree fits most of my parameters as well so I spent a little time digging into the company further.
Hot Oil Stocks To Buy For 2021: Adaptimmune Therapeutics plc(ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companys lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. Adaptimmune Therapeutics plc has collaboration agreement with Universal Cells Inc. for the development of allogeneic T-cell therapies. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
- [By Logan Wallace]
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
- [By Stephan Byrd]
Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by stock analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Monday.
- [By Logan Wallace]
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
Get Adaptimmune Therapeutics alerts:
Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) to Post -$0.28 Earnings Per Share (americanbankingnews.com) Peritoneal Cancer Market Pipeline Review H1- Target Drug Profile, Top Industry Intelligence, Major Key Players and … (thefreenewsman.com) Escherichia coli Infections Market Research Report Pipeline Review H1 Assessment by Mechanism of Action, Drug … (theperfectinvestor.com) Adaptimmune Therapeutics plc (ADAP): Do You Have This Stock in Portfolio?: (bitcoinpriceupdate.review)
Several equities analysts have weighed in on the company. Leerink Swann reissued an “outperform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, March 15th. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday. SunTrust Banks increased their target price on Adaptimmune Therapeutics to $18.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.94.